Tofacitinib, targeting JAK1 and JAK3, and JAK2 to a lesser extent, was the first JAKi approved by FDA and The European Medicines Agency (EMA) for treatment patients with moderate to severe RA, failing initial treatment with methotrexate (MTX) or other csDMARDs. The gene discussed is JAK1; the disease is rheumatoid arthritis.